Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ChromaDex Announces Top-line Results of its Second Human Clinical Trial - Nutraceuticals World

What are you searching for?

Sign in
Market Updates, Research

ChromaDex Announces Top-line Results of its Second Human Clinical Trial

Study establishes an effective dose range and validates safety for NIAGEN.

By: Lisa Olivo

, Rodman Media

Initial results of its second human clinical study of NIAGEN nicotinamide riboside chloride (NR) from ChromaDex Corp. have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over eight weeks.

In this study, participants in the active group received 100, 300, or 1000 mg per day. Results from the randomized, double-blind, placebo controlled, parallel-arm trial demonstrated that NR produced statistically significant increases in blood NAD+ compared to placebo that were related to the dose of NR consumed, demonstrating a dose response. Levels remained elevated throughout the duration of the study, thereby establishing an efficacious range for daily consumption. The study confirms not only efficacy in raising NAD+, but also definitively documents the safety of daily use of NR.  

Frank Jaksch Jr., founder and CEO of ChromaDex, commented, “This study is a pivotal milestone in the clinical science of NIAGEN and is key to better understanding its role in human health. For the first time, we have established an effective dose range for long term use in humans. This paves the way for important clinical work in the modulation of aging, as well as in other health-related categories.”

Maintenance of sufficient levels of NAD+ is key to cellular energy metabolism and mitochondrial function, according to ChromaDex. Cellular energy not only fuels our most basic bodily functions, it is also necessary to defend against oxidative stress in the body, repair DNA damage, and create the building blocks for DNA and RNA. In humans and animals, NAD+ levels decrease in normal aging. This observation has led to dozens of published preclinical studies demonstrating the efficacy of NIAGEN in raising NAD+, as well as some of the potential mechanisms by which NIAGEN can help reduce the metabolic stresses of normal aging.

Study publication in peer review literature will be critically important for supporting future University and NIH-Sponsored clinical efficacy trials. The full results of the study will be submitted for publication in a peer review 

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics